Clinical and Immunological Correlates of Pre-Co-Seasonal Sublingual Immunotherapy with Birch Monomeric Allergoid in Patients with Allergic Rhinoconjunctivitis
Free accessResearch articleFirst published online April, 2009
Clinical and Immunological Correlates of Pre-Co-Seasonal Sublingual Immunotherapy with Birch Monomeric Allergoid in Patients with Allergic Rhinoconjunctivitis
Sublingual immunotherapy is safe and efficacious in the treatment of patients with allergic rhinitis. The clinical and biological efficacy of modified allergens (allergoids) has not been fully clarified. We investigated in birch allergic patients the effect of a pre-co-seasonal sublingual immunotherapy regimen with a modified allergen extract on clinical parameters and on T cell proliferation and regulatory cytokine production (IL-10, TGF-beta). We found that during the birch pollen season symptoms and drug usage scores were 30 and 40% improved, respectively, in treated versus control subjects (p<0.0001 for both comparisons) whereas well days were 23.5 (33%) versus 16.9 (23%) (p=0.0024), respectively. Bet v 1 allergen specific proliferation decreased (p = 0.0010), whereas IL-10 transcription increased (p = 0.0010) in treated, but not in control patients. Moreover, TGF-beta transcription was increased, although not significantly (p=0.066), following immunotherapy. Thus, sublingual immunotherapy with modified allergen in birch-allergic subjects was safe, clinically efficacious and associated with the reduction of allergen-specific proliferation and with the increased production of the IL-10 regulatory cytokine.
BousquetJLockeyRMallingHJ. Allergen immunotherapy: Therapeutic vaccines for allergic diseases. A WHO position paper. J Allergy Clin Immunol1998; 102:558–62.
2.
AalberseRCvan der GaagRvan LeeuwenJ. Serologic aspects of igg4 antibodies. I. Prolonged immunization results in an IgG4-restricted response. J Immunol1983; 130:722–6.
3.
AkdisCABleskenTAkdisMWuthrichBBlaserK. Role of interleukin 10 in specific immunotherapy. J Clin Invest1998; 102:98–106.
4.
AkdisMVerhagenJTaylorA. Immune responses in healthy and allergic individuals are characterized by a fine balance between allergen-specific t regulatory 1 and T helper 2 cells. J Exp Med2004; 199:1567–75.
5.
CanonicaGWPassalacquaG. Non-injection routes for immunotherapy. J Allergy Clin Immunol2003; 111:437–48.
6.
BurasteroSE. Sublingual immunotherapy for allergic rhinitis: An update. Curr Opin Otolaryngol Head Neck Surg2006; 14:197–201.
7.
NovembreEGalliELandiF. Coseasonal sublingual immunotherapy reduces the development of asthma in children with allergic rhinoconjunctivitis. J Allergy Clin Immunol2004; 114:851–7.
8.
BousquetJVan CauwenbergePKhaltaevN. Allergic rhinitis and its impact on asthma. J Allergy Clin Immunol2001; 108:147–334.
9.
WilsonDRLimaMTDurhamSR. Sublingual immunotherapy for allergic rhinitis: Systematic review and meta-analysis. Allergy2005; 60:4–12.
10.
BagnascoMMarianiGPassalacquaG. Absorption and distribution kinetics of the major parietaria judaica allergen (Par j 1) administered by non-injectable routes in healthy human beings. J Allergy Clin Immunol1997; 100:122–9.
11.
BagnascoMAltrinettiVPesceG. Pharmacokinetics of Der p 2 allergen and derived monomeric allergoid in allergic volunteers. Int Arch Allergy Immunol2005; 138:197–202.
12.
MacatoniaSEHoskenNALittonM. Dendritic cells produce IL-12 and direct the development of th1 cells from naive cd4+ t cells. J Immunol1995; 154:5071–9.
13.
PassalacquaGAlbanoMRiccioAFregoneseLPuccinelliPParmianiSCanonicaGW. Clinical and immunologic effects of a rush sublingual immunotherapy to parietaria species: A double-blind, placebo-controlled trial. J Allergy Clin Immunol1999; 104:964–8.
14.
MarcucciFSensiLDi CaraGSalvatoriSBerniniMPecoraSBurasteroSE. Three-year follow-up of clinical and inflammation parameters in children monosensitized to mites undergoing sub-lingual immunotherapy. Pediatr Allergy Immunol2005; 16: 519–26.
15.
CosmiLSantarlasciVAngeliR. Sublingual immunotherapy with dermatophagoides monomeric allergoid down-regulates allergen-specific immunoglobulin E and increases both interferon-gamma- and interleukin-10-production. Clin Exp Allergy2006; 36:261–72.
16.
ArikanCBahcecilerNNDenizGAkdisMAkkocTAkdisCABarlanIB. Bacillus calmette-guerininduced interleukin-12 did not additionally improve clinical and immunologic parameters in asthmatic children treated with sublingual immunotherapy. Clin Exp Allergy2004; 34:398–405.
17.
SavolainenJJacobsenLValovirtaE. Sublingual immunotherapy in children modulates allergen-induced in vitro expression of cytokine mRNA in PBMC. Allergy2006; 61:1184–90.
18.
CiprandiGFenoglioDCirilloIVizzaccaroAFerreraAToscaMAPuppoF. Induction of interleukin 10 by sublingual immunotherapy for house dust mites: A preliminary report. Ann Allergy Asthma Immunol2005; 95:38–44.
19.
SavolainenJNieminenKLaaksonenK. Allergen-induced in vitro expression of il-18, slam and gata-3 mRNA in PBMC during sublingual immunotherapy. Allergy2007; 62:949–53.
BousquetJKhaltaevNCruzAA. Allergic rhinitis and its impact on asthma (ARIA) 2008 update (in collaboration with the world health organization, GA(2)LEN and allergen). Allergy2008; 86:8–160.
22.
BatemanEDHurdSSBarnesPJ. Global strategy for asthma management and prevention: GINA executive summary. Eur Respir J2008; 31:143–78.
23.
HollandPMAbramsonRDWatsonRGelfandDH. Detection of specific polymerase chain reaction product by utilizing the 5′-3′ exonuclease activity of Thermus aquaticus DNA polymerase. Proc Natl Acad Sci USA1991; 88:7276–80.
24.
BurasteroSEMistrelloGFalagianiP. Effect of sublingual immunotherapy with grass monomeric allergoid on allergen-specific T-cell proliferation and interleukin 10 production. Ann Allergy Asthma Immunol2008; 100:343–50.
25.
FantaCBohleBHirtW. Systemic immunological changes induced by administration of grass pollen allergens via the oral mucosa during sublingual immunotherapy. Int Arch Allergy Immunol1999; 120:218–24.
26.
Rolinck-WerninghausCKoppMLiebkeCLangeJWahnUNiggemannB. Lack of detectable alterations in immune responses during sublingual immunotherapy in children with seasonal allergic rhinoconjunctivitis to grass pollen. Int Arch Allergy Immunol2005; 136:134–41.
27.
DehlinkEEiweggerTGerstmayrM. Absence of systemic immunologic changes during dose buildup phase and early maintenance period in effective specific sublingual immunotherapy in children. Clin Exp Allergy2006; 36:32–9.
28.
BohleBKinaciyanTGerstmayrMRadakovicsAJahn-SchmidBEbnerC. Immune mechanisms underlying successful sublingual immunotherapy: Transient induction of CD4+CD25+ T cells suppressive through IL-10 is followed by long-term allergen-restricted peripheral tolerance and immune deviation: World Immune Regulation Meeting. Davos, Switzerland, 2007, 1, pp 110.
29.
RossiREMonasteroloG. A pilot study of feasibility of ultra-rush (20–25 minutes) sublingual-swallow immunotherapy in 679 patients (699 sessions) with allergic rhinitis and/or asthma. Int J Immunopathol Pharmacol2005; 18:277–85.
30.
RossiREMonasteroloGCocoGOpertiD. Possible relationship between systemic side effects and sensitization to rPar j 2 in allergic patients submitted to an ultra-rush (20 min) sublingual immunotherapy and selected by component resolved diagnosis. Int Arch Allergy Immunol2005; 138:105–10.
31.
KhinchiMSPoulsenLKCaratFAndreCHansenABMallingHJ. Clinical efficacy of sublingual and subcutaneous birch pollen allergen-specific immunotherapy: A randomized, placebo-controlled, double-blind, double-dummy study. Allergy2004; 59:45–53.
32.
RakSHeinrichCScheyniusA. Comparison of nasal immunohistology in patients with seasonal rhinoconjunctivitis treated with topical steroids or specific allergen immunotherapy. Allergy2005; 60:643–9.
33.
NelsonHS. Allergen immunotherapy: Where is it now?J Allergy Clin Immunol2007; 119:769–79.
